Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation.
Journal Information
Full Title: J Immunother Cancer
Abbreviation: J Immunother Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"for each epitope the tcr with the highest cytolytic activity among the three was regarded as the top candidate tcr and was used to manufacture cmv-tcr-t cells in the clinical study 10 1136/jitc-2023-007735 supp1 supplementary data 10 1136/jitc-2023-007735 supp2 supplementary data full-length cdna sequences of tcr?"
"Competing interests: None declared."
"Funding: This work was partially supported by grants from the National Natural Science Foundation of China (nos. 82070178, 82270162, 82270224, and 82200169), the National Key R&D Program of China (2023YFC2507800 and 2021YFA1100904), the Beijing Natural Science Foundation of China (no. 7222175), military medical support innovation and generate special program (21WQ034), Special Research Found for Health Protection (21BJZ30), and the Logistics Independent Research Program (2023hqzz09)."
"Trial registration number ClinicalTrials.gov Registry (NCT05140187)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025